Posted on by admin

Menopause Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight Pfizer, Hoffmann-La Roche, Mithra Pharmaceuticals, Bayer, Nerre Therapeutics, Astellas Pharma, GlaxoSmithKline

Menopause Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight Pfizer, Hoffmann-La Roche, Mithra Pharmaceuticals, Bayer, Nerre Therapeutics, Astellas Pharma, GlaxoSmithKline
The Key Menopause Companies in the market include – Pfizer, Hoffmann-La Roche, Mithra Pharmaceuticals, Bayer, Nerre Therapeutics, Astellas Pharma, GlaxoSmithKline, Mitsubishi Tanabe Pharma, Centro A.F. de Estudios, Fervent Pharma, Schaper & Bruemmer GmbH, Watson Pharma, Ausio Pharma, Unimed Pharma, and others.

 

DelveInsight’s “Menopause Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Menopause, historical and forecasted epidemiology as well as the Menopause market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Menopause market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Menopause Market Forecast

 

Some of the key facts of the Menopause Market Report: 

  • The Menopause market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In September 2024, Bonafide Health, LLC, a women’s healthcare company dedicated to offering effective and clinically validated solutions for common perimenopause and menopause symptoms, has announced the launch of Thermella. This hormone-free, prescription-free option alleviates hot flashes and night sweats. Thermella acts as a neurokinin 3 receptor (NK3R) antagonist, addressing symptoms at the source within as little as two weeks by rebalancing the body’s thermoregulatory center through the blockade of the neurokinin B (NKB) pathway. This mechanism of action is similar to that of current prescription options, including VeozahTM.

  • In 2022, Astellas Pharma announced that the US FDA and EMA accepted the NDA for fezolinetant

  • According to a study by Peacock et al. [2022], in the United States, approximately 1.3 million women become menopausal each year, among them about 5% of women experience early menopause between the ages of 40 and 45

  • As per the North American Menopause Society [2021], up to 75% of females in the United States experience hot flashes around menopause

  • According to British Menopause Society [2021], menopausal symptoms affect more than 75% of women, and over 25% describe severe symptoms that may last for about 7 years, and 1 in 3 women experience symptoms beyond the 7 years

  • According to a global survey by Nappi et al. [2021], prevalence of moderate-to-severe VMS was higher in Europe (40 %) than the US (34 %); both were higher than Japan (16 %)

  • Key Menopause Companies: Pfizer, Hoffmann-La Roche, Mithra Pharmaceuticals, Bayer, Nerre Therapeutics, Astellas Pharma, GlaxoSmithKline,  Mitsubishi Tanabe Pharma,  Centro A.F. de Estudios, Fervent Pharma, Schaper & Bruemmer GmbH, Watson Pharma,  Ausio Pharma, Unimed Pharma, and others

  • Key Menopause Therapies: DONESTA, Fezolinetant, Paroxetine, Elinzanetant, Elismetrep, DVS-233, Estradiol and Progesterone, FP-101, Black Cohosh, Premarin®, ibandronate, S-equol, MELSMON, and others

  • The Menopause epidemiology based on gender analyzed that vasomotor symptoms are more prevalent in menopausal women than other symptoms like sleep disturbances and weight gain

  • The Menopause market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Menopause pipeline products will significantly revolutionize the Menopause market dynamics.

 

Menopause Overview

According to the North American Menopause Society (NAMS), menopause is a routine, non-pathologic condition involving the permanent cessation of menses for at least 12 months. Menopause occurs in all menstruating females due to non-pathologic estrogen deficiency. The median age of menopause is 51. Worldwide, an estimated 25 million women enter this phase of life every year.

 

Get a Free sample for the Menopause Market Report:

https://www.delveinsight.com/report-store/menopause-market-forecast

 

Menopause Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Menopause Epidemiology Segmentation:

The Menopause market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Menopause

  • Prevalent Cases of Menopause by severity

  • Gender-specific Prevalence of Menopause

  • Diagnosed Cases of Episodic and Chronic Menopause

 

Download the report to understand which factors are driving Menopause epidemiology trends @ Menopause Epidemiology Forecast

 

Menopause Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Menopause market or expected to get launched during the study period. The analysis covers Menopause market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Menopause Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Menopause Therapies and Key Companies

  • DONESTA: Mithra Pharmaceuticals

  • Fezolinetant: Astellas Pharma

  • Paroxetine: GlaxoSmithKline

  • Elinzanetant: Bayer/Nerre Therapeutics

  • Elismetrep: Mitsubishi Tanabe Pharma

  • DVS-233: Pfizer

  • Estradiol and Progesterone: Centro A.F. de Estudios Tecnologicos, S.A.

  • FP-101: Fervent Pharma

  • Black Cohosh: Schaper & Bruemmer GmbH

  • Premarin®: Watson Pharma

  • ibandronate: Hoffmann-La Roche

  • S-equol: Ausio Pharma

  • MELSMON: Unimed Pharma

 

Discover more about therapies set to grab major Menopause market share @ Menopause Treatment Market

 

Menopause Market Strengths

  • Many pharmaceutical companies are continuously researching and innovating the treatment regimens for eradicating the current unmet needs in menopause

  • The increasing prevalence of menopause, for instance, knee pain associated with osteoarthritis, is primarily contributed by the increase in the aging population that will likely impact the market in the near future

 

Menopause Market Unmet Needs

  • Challenges in diagnoses

  • Development of novel therapies

  • Limitations in gene therapy

  • Poor disease understanding

  • Clinical biomarkers

 

Scope of the Menopause Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Menopause Companies: Pfizer, Hoffmann-La Roche, Mithra Pharmaceuticals, Bayer, Nerre Therapeutics, Astellas Pharma, GlaxoSmithKline,  Mitsubishi Tanabe Pharma,  Centro A.F. de Estudios, Fervent Pharma, Schaper & Bruemmer GmbH, Watson Pharma,  Ausio Pharma, Unimed Pharma, and others

  • Key Menopause Therapies: DONESTA, Fezolinetant, Paroxetine, Elinzanetant, Elismetrep, DVS-233, Estradiol and Progesterone, FP-101, Black Cohosh, Premarin®, ibandronate, S-equol, MELSMON, and others

  • Menopause Therapeutic Assessment: Menopause current marketed and Menopause emerging therapies

  • Menopause Market Dynamics:  Menopause market drivers and Menopause market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Menopause Unmet Needs, KOL’s views, Analyst’s views, Menopause Market Access and Reimbursement 

 

To know more about Menopause companies working in the treatment market, visit @ Menopause Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Menopause Market Report Introduction

2. Executive Summary for Menopause

3. SWOT analysis of Menopause

4. Menopause Patient Share (%) Overview at a Glance

5. Menopause Market Overview at a Glance

6. Menopause Disease Background and Overview

7. Menopause Epidemiology and Patient Population

8. Country-Specific Patient Population of Menopause 

9. Menopause Current Treatment and Medical Practices

10. Menopause Unmet Needs

11. Menopause Emerging Therapies

12. Menopause Market Outlook

13. Country-Wise Menopause Market Analysis (2020–2034)

14. Menopause Market Access and Reimbursement of Therapies

15. Menopause Market Drivers

16. Menopause Market Barriers

17.  Menopause Appendix

18. Menopause Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/